An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.
In plain words · Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally.
VERDICT
The label
Markup
read at $164.06
Insulet Corporation holds its Markup at $164.06.
PHPhase · the trend structure carries the Markup label
INInsiders · no filings inside 60 days, left as found
POPositioning · no disclosures inside 60 days, left as found
OPOptions · no verdict drawn today, left as found
SCScreen · passes the values gate
edge confirmed
edge broken
edge forming
Each arm is one independent read. Conviction is not a single call, it is how many edges converge.
INVESTOR
The investor read · the season, not the day
As held on the ledger · 2026-07-19
Phase
Markup
Quantitative state
Elevated stress, defensive posture warranted, held for 18 days
Price
$164.06
Valuation
38.33 trailing · 20.37 forward price to earnings
Values screen
PASS· score 75.9
Beta
1.11
OPPORTUNITY
The opportunity · what the numbers say it is worth
Our framework reads OPPORTUNITY — it trades at roughly a 29% discount to our $211.10 fair value, moderate competitive moat, 33.90% revenue growth.
Read at
$164.06
38.33 P/E · 20.37 fwd
Our fair value
$211.10
29% discount
Analyst target (avg)
$245.00
+49% to current
Target low $172.00Analyst target rangeTarget high $360.00
▲ current $164.06 · | average target
Price history & projections · where it has been, where the models see it going
The valuation journey · where the price sits against fair value and the Street
Current
$164.06
you are here
Conservative
$154.80
-6%
Analyst avg
$245.00
+49%
Our fair value
$211.10
+29%
Analyst high
$360.00
+119%
Green marks levels above today's price, red below; the shaded band is the gap between the price and our fair value.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Revenue growth
33.90%
Profit margin
10.44%
Debt to equity
77.84
Analyst consensus
Strong Buy · 23 covering
Fair value and rating are our own model estimates; target range reflects third-party analyst estimates. Analysis, not advice.
SCREEN
The values screen, explained · five checks, plain English
This company clears both standards. There are two widely recognised ways to check whether a company is suitable for a Muslim investor. Here is how it did on each:
The common standard· AAOIFI Used by most halal investing apps✓ PASSES
Our stricter standard· asset-based The one Titan applies✓ PASSES
Business activityIts core business isn't built on prohibited lines — no gambling, alcohol, tobacco, weapons, or interest-based lending.Pass
Debt loadInterest-bearing debt is just 29.8% of its assets, well under the one-third ceiling — it does not run on borrowed money.Pass
Interest-bearing cashCash held in interest-bearing accounts and securities is 0.0% of assets, under the one-third limit.Pass
ReceivablesMoney owed to the company is 38.5% of assets, under the 49% limit.Pass
Revenue purityOnly 1.3% of revenue comes from non-compliant sources — under the 5% line.Pass
Every security is read against two recognised standards: our stricter asset-based screen (ratios measured against total assets) and the more widely used market-value standard (measured against market capitalisation). Where they agree we say so plainly; where they part ways — almost always on the debt check — we show both readings and mark it, because that disagreement is the finding, not a fault. We report the score; you and your scholar make the call.
PLAIN
The business, in plain words · what the numbers mean
Diabetics swap tubes and injections for one pod
Every insulin user knows the daily grind of tubes, site changes and manual calculations. Insulet's Omnipod 5 removes most of that friction and the numbers show adoption accelerating. Revenue is rising 34 percent, return on equity sits at 23 percent and the forward multiple is 20.4 times with a moderate moat protecting the platform.
The shares trade at 164 dollars against our 211 dollar fair value, a 29 percent margin of safety. Profit margins are already 10 percent and 23 analysts carry a strong buy consensus with a 245 dollar median target. The ethical screen clears cleanly on product safety and access.
Growth still depends on insurance coverage and hospital formulary wins, both of which can shift quickly. Competition from larger device makers remains real and any slowdown in new patient starts would hit the top line fast. Analysis, not advice.
Screened names in the same industry · explore each on its own page.
TRADE
Where & how to trade · wherever in the world you are
PODD trades on a US exchange. As a US-listed security it is accessible through almost any international broker offering US markets. New to this, or investing from outside the US? Our guide to accessing global markets covers brokers, currencies and the practical steps.
TRADER
The trader read · the latest dated commentary
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 50%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (24 analysts) rates it buy, with a mean price target of $247. Entered 2026-07-18 · Distribution
JOURNAL
The dated journal · newest first, never edited
2026-07-18Distribution$153.22+0.0%Entry 3
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bearish. Over the past year the shares are down 50%. Our forward projection puts the odds of a 10% gain over the next month near 20%. The street (24 analysts) rates it buy, with a mean price target of $247.
2026-07-03Distribution$153.22+0.0%Entry 2
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Price has moved down 0.0% since our last review. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns.
2026-07-02Distribution$153.22Entry 1
The framework reads distribution. Smart money appears to be selling into strength. Institutional holders may be rotating out. Ethical screening: PASS with strong ethical credentials. The risk-adjusted return profile shows negative risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
